• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Gynesonics touts pivotal IDE Sonata trial results

Gynesonics touts pivotal IDE Sonata trial results

January 9, 2018 By Fink Densford

Gynesonics

Gynesonics today released results from the pivotal FDA investigational device exemption cleared trial for its Sonata system designed for the incision-free treatment of uterine fibroids, touting a 99% freedom from surgical reintervention for heavy menstrual bleeding.

The Redwood City, Calif.-based company’s Sonata trial is a prospective, longitudinal, multi-center trial exploring the safety and effectiveness of its Sonata device, which is designed to use sonograph-guided radiofrequency ablation to destroy intrauterine fibroids while preserving the uterus.

Results from the trial indicated that 99% of trial patients were free from surgical reintervention at 12 months. A total of 94% of patients treated with the Sonata reported a reduction in bleeding, with 64% achieving a greater than or equal to 50% reduction in bleeding.

Data also indicated that 97% of patients in the trial were satisfied with the procedure and would recommend it to friends, with most patients returning to normal activity the day after the procedure.

“The actual results achieved in the Sonata trial far exceed the required thresholds established by the FDA for the co-primary end points of reduction in menstrual bleeding and freedom from surgical reintervention for bleeding. These results, along with the impressive levels of patient satisfaction and rapid return to normal activity achieved, clearly demonstrate the potential for Sonata as a first line treatment for symptomatic fibroids,” principal investigator Scott Chudnoff of Connecticut’s Stamford Hospital said in a prepared statement.

“In light of the recent controversies in gynecologic surgery which are impacting access for women to existing minimally invasive fibroid treatment options, it is important that new innovations be made available. Sonata provides our patients with an incision-free transcervical treatment for most types and sizes of fibroids. The impressive patient outcomes achieved with the Sonata system demonstrate its potential to cause a paradigm shift away from more invasive surgical procedures in addressing this significant quality of life issue for women,” trial investigator Dr. Charles Miller said in prepared remarks.

“While these impressive results achieved with Sonata in this pivotal trial are an important milestone for women and physicians, it is the consistency of the clinical effect of our technology achieved when compared alongside the previously published FAST-EU trial that is truly noteworthy. Considering these two prospective, multicenter trials were comprised of several disparate patient populations across two continents, and performed by a broad range of physician operators across various healthcare delivery systems and clinical settings, the consistency of these results is remarkable. The reproducible results highlight the robustness of the Sonata platform design and its potential to become a new standard of care for fibroid treatment,” prez & CEO Chris Owens said in a press release.

Last month, Gynesonics said it submitted its 510(k) Premarket Notification to the FDA for its Sonata System.

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Women's Health Tagged With: Gynesonics

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy